- Market cap
- Revenue
- Net income
- Cash on hand
- Gross margin
- Net margin
- EPS
- P/E ratio
Enanta Pharmaceuticals Announces First Participant Dosed in Phase 1 Clinical Trial of EDP-978, an Oral, Once-Daily KIT Inhibitor, in Development for the Treatment of Urticaria Enanta Pharmaceuticals Announces Advancement of its Zelicapavir Clinical Development Program for the Treatment of Respiratory Syncytial Virus Enanta Pharmaceuticals’ Partner AbbVie Receives European Commission Approval of MAVIRET® (Glecaprevir/Pibrentasvir) for People […] The post 2026 appeared first on Enanta Pharmaceuticals.
Enanta Pharmaceuticals’ Partner AbbVie Receives U.S. FDA Approval of an Expanded Indication for MAVYRET® (glecaprevir/pibrentasvir) as the First and Only Treatment for People with Acute Hepatitis C Virus Enanta Pharmaceuticals Reports Positive Topline Results from its Phase 2b Study of Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV) in High-Risk Adults The post 2025 appeared first on Enanta Pharmaceuticals.
The post SARS-CoV-2 Resistance Pathways to EDP-235 appeared first on Enanta Pharmaceuticals.
The post Zelicapavir Update appeared first on Enanta Pharmaceuticals.
The post Zelicapavir Reduces Symptom Duration and Hospitalization in a Randomized, Double-Blind, Placebo-Controlled, International, Phase 2 Trial appeared first on Enanta Pharmaceuticals.
The post EPS-3903 is a Potent and Selective Oral STAT6 Inhibitor That Blocks Th2 Inflammation in a House Dust Mite-Induced Asthma Mouse Model appeared first on Enanta Pharmaceuticals.
The post EPS-3903, a Potent, Oral STAT6 Inhibitor, Exhibits Preferential Lung and Alveolar Macrophage Distribution with Low Drug–Drug Interaction Potential for the Treatment of Asthma appeared first on Enanta Pharmaceuticals.
The post Zelicapavir Demonstrates High Clinical and Functional Barrier Against Antiviral Resistance: Results from a Randomized Double-Blind Placebo-Controlled Pediatric RSV Antiviral Clinical Trial appeared first on Enanta Pharmaceuticals.
The post Zelicapavir Decreases Symptom Duration, Hospitalization and Viral Load in a Global, Randomized, Double-Blinded, Placebo-Controlled Phase II Trial of High-Risk Adults with RSV appeared first on Enanta Pharmaceuticals.
The post Potent STAT6 Inhibitor EPS-3903 Has Excellent Preclinical Pharmacokinetics Enabling Sustained STAT6 Inhibition with Once-Daily Oral Dosing in Humans appeared first on Enanta Pharmaceuticals.